Donate
Back to Clinical Trials
Back to Clinical Trials

Brief Title: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

INTRODUCTION

  • Org Study ID: RMC-5552-001
  • Secondary ID: N/A
  • NCT ID: NCT04774952
  • Sponsor: Revolution Medicines, Inc.

BRIEF SUMMARY

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

DETAILED DESCRIPTION

This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.

  • Overall Status
    Recruiting
  • Start Date
    April 7, 2021
  • Phase
    Phase 1
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Solid Tumors

ELIGIBILITY

Inclusion Criteria:
* Participants (male or female) ≥18 years of age

- * Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type

- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- * Participants in the Dose-Expansion Component must have molecular aberrations in the mTOR pathway

- * Adequate hematologic, hepatic and renal function
Exclusion Criteria:
* Known or suspected leptomeningeal or brain metastases or spinal cord compression

- * Primary central nervous system (CNS) tumors

- * Clinically significant cardiac disease

- * Active, clinically significant interstitial lung disease or pneumonitis

- * Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2 diabetes are excluded.

- * Subjects with stomatitis or mucositis of any grade

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Revolution Medicines, Inc

Role: Study Director

Affiliation: Revolution Medicines, Inc.

Overall Contact

Name: Revolution Medicines, Inc.

Phone: (650) 779-2300

Email: CT-Inquiries@RevMed.com

LOCATION

Facility Status Contact

Read Our Stories